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Results: A total of 48 stents from 24 pigs were harvested. There is no acute in-stent
thrombosis formation during the trial. After 90 days, percent diameter stenosis (%
DS), late loss (LL), and percent area stenosis (%AS) of Ni-Ti sirolimus-eluting
stents was (10.90.3) %, (0.310.02) mm and (23.13.7) %. Histomorphometric
analysis showed no signiﬁcant difference in reducing neointimal hyperplasia
compared to EXCELTM stent in porcine coronary models. No inﬂammatory re-
action was observed around the stent strut of Ni-Ti based stent after 90 days. It
might take 90 days for Ni-Ti sirolimus-eluting stents to complete its re-
endothelialization.
Conclusions: Ni-Tisirolimus-eluting stents with bioabsorbable polymer showed
excellent biocompatibility in porcine model. It is proved that this new DES system
can inhibit neointimal hyperplasia and decrease in-stent stenosis with safety and
efﬁcacy.GW25-e2518
A study of quality of life in patients with coronary heart disease after drug-
eluting stent implantation
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Objectives: To investigate the quality of life (QOL) after drug-eluting stent (DES)
implantation in patients with coronary heart disease (CHD) and its related factors, so
that we can provide more targeted treatment and guidance for the future of this kind of
patients.
Methods: 132 patients with CHD treated were selected as object of the study.
The patients were voluntary to accept DES implantation for treatment. A ques-
tionnaire survey was conducted before and after drug-eluting stent implantation
for 6 months with SF-36 Questionnaire, Settle Angina Questionnaire (SAQ) and
self-designed basic information questionnaire of patients. The aim is to analyze
the QOL in different gender, age, place of residence, education level and other
risk factors before and after patients with CHD treated with DES and its related
factors.
Results: (1) Scores for physical component summary (PCS), mental component
summary (MCS) and eight categories, Seattle Angina Questionnaire (SAQ) score
and ﬁve categories were better signiﬁcantly after the patients with DES implantation
for 6 months compared with before (all P<0.01). (2) After DES implantation:
The postoperative PF, role-physical (RP), VT, mental health (MH) of patients whose
age <60 years were better than patients whose age 60 years
(86.329.09vs.78.679.55, 69.3626.77vs.51.6719.62, 84.569.12vs.78.7.62,
81.5710.35vs.76.4019.98, all P<0.05); The PF, RP, VT, MH of male patients
were better than female patients (86.329.09vs.78.679.55, 69.3626.77vs
.51.6719.62, 84.569.12vs.78.837.62, 81.5710.35vs.76.4010.98, all P
<0.05). The BP, SF, physical limitation (PL), AS, and AF of patients whose chronic
coronary artery disease (CAD) before operation were better than patients whose
acute coronary syndrome (ACS) (31.4315.42vs.26.9315.66, 60.1216.11vs.
42.6812.09, 39.269.77vs.34.419.03, 34.5214.74vs.24.7717.35, 22.86
8.45vs.9.559.28, all P<0.05), and the difference disappeared after operation.
Patients whose LVEF>50% were better in RP, VT, SF, RE, MH and AS than
those whose LVEF 50% after operation (68.5822.85vs.48.68
34.83,82.968.12vs.74.4712.79, 84.9612.06vs.73.0213.34, 87.9117.85vs.
73.6921.02, 80.219.81vs.71.5812.50, 91.1514.91vs.82.8918.73, all
P<0.05). (3) Age, LVEF, complications, gender and BMI were factors which inﬂect
the QOL after DES implantation for 6 months (PCS: Beta - 0.399, 0.260, -0.256,
-0.229, -0.206, all P<0.05). The patients who had more complications, higher age,
higher BMI, female and lower LVEF had worse QOL.
Conclusions: DES can signiﬁcantly improve the QOL in patients with CHD; The
main factors affected the QOL in patients with CHD were age, gender, BMI, com-
plications, gender and LVEF.GW25-e0055
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Objectives: Arterial stiffness is an independent predictor for vascular diseases. Car-
dio-ankle vascular index (CAVI) is a new index of arterial stiffness. However, there
was little research about the CAVI value between different countries. The aim of the
present study was to compare CAVI between Chinese and Japanese subjects and to
assess related factors.
Methods: 2519 healthy persons [1245 Chinese (M/F, 524/721) and 1274 Japanese
(M/F, 534/740)] from department of physical examination were enrolled into our
study. CAVI was recorded using a VaseraVS-1000 vascular screening system.JACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/CResults: CAVI was increasing with aging in all subjects. CAVI was signiﬁcantly
lower in Chinese compared with Japanese both in male and female. There was dif-
ference in lipid metabolism between these two groups. Multivariate analysis showed
that age, systolic blood pressure (SBP), fasting plasma glucose (FPG), plasma
creatinine (Cr) were signiﬁcant independent associating factors of CAVI in Chinese
persons (b¼0.548,P<0.001; b¼0.129, P¼0.001; b¼0.105, P¼0.006; and b¼0.100,
P¼0.012, respectively), whereas age, SBP, high density lipoprotein cholesterol (HDL-
C), Cr, body mass index (BMI), FPG were signiﬁcant independent associating factors
of CAVI in Japanese subjects (b¼0.669, P<0.001; b¼0.198, P<0.001; b¼ -0.079,
P<0.001; b¼0.090, P<0.001; b¼ -0.124, P<0.001; b¼0.055, P¼0.009;
respectively).
Conclusions: CAVI was increasing with aging in both Chinese and Japanese subjects.
CAVI was signiﬁcantly lower in Chinese than in Japanese subjects. Age, SBP, FPG
and creatinine were independently associated with CAVI in both Chinese and Japa-
nese subjects.GW25-e0401
Drug-coated balloon versus drug-eluting stent in the treatment of patients
with in-stent restenosis: A meta-analysis of randomized controlled trials
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Objectives: With the development of drug-eluting stent (DES), it has drastically cut
the incidence of in-stent restenosis (ISR). However, the management of DES-ISR is
particularly challenging. Drug-coated balloon (DCB) is a new choice for ISR, and is
an established treatment for ISR after prior bare metal stent and recommended by
present European revascularization guidelines. Several randomized controlled trials
(RCTs) have been developed, but they are compact and the clinical and angiographic
results are not consistent. Thus, we propose to compare the difference of safety and
effectiveness between DCB and DES in the treatment of ISR by the present meta-
analysis of RCTs.
Methods: EMBASE, PubMed, CENTRAL and Google Scholar were compre-
hensively searched in March 2014 for eligible RCTs where patients with
ISR were randomly assigned to either DCB or DES treatment. Endpoints of
interest were all cause death, major adverse cardiac events (MACEs),
target lesion revascularization (TLR), binary restenosis and late lumen loss
(LLL). A ﬁxed-effect model was ﬁrstly utilized to calculate the pooled odds
risk (OR) and standardized mean difference (SMD) with 95% conﬁdence in-
tervals (CIs).
Results: Four studies involving 808 patients were identiﬁed that fulﬁlled the inclusion
criteria in this analysis. Mean follow-up duration was 12 months. For all cause death
(OR 0.809, 95% CI 0.346 to 1.889, P ¼ 0.624, I2 ¼ 27.6%), MACEs (OR 1.033, 95%
CI 0.712 to 1.499, P ¼ 0.863, I2 ¼ 14.6%), TLR (OR 1.320, 95% CI 0.585 to 2.978,
P ¼ 0.504, I2 ¼ 60.5%), binary restenosis (OR 1.012, 95% CI 0.693 to 1.476,
P ¼ 0.951, I2 ¼ 30.9%), and LLL (SMD -0.065, 95% CI -0.315 to 0.185, P ¼ 0.611,
I2 ¼ 67.1%). Among the measurements listed above, TLR and LLL were pooled with
a random-effects model because of heterogeneity. Based on these results, we can
conclude that the outcomes of the comparison between DES and DCB have no sig-
niﬁcant difference.
Conclusions: Being compared to DES, DCB is non-inferior whether on the safety or
effectiveness. Furthermore, DCB use will be polymer-free to reduce the risk of late
thrombosis, decrease the duration of dual antiplatelet therapy and avoid the “onion-
skin” phenomena. Thus, DCB could be considered a promising choice for the treat-
ment of ISR in selected clinical settings.GW25-e0566
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Objectives: Recent studies have demonstrated that serum cystatin C (CyC)
strengthens the association between the eGFR and the risk of death and end-
stage renal disease. Patients with contrast induced-acute kidney injury have
greatly increased risks of cardiovascular events and cardiovascular deaths
after percutanous coronary intervention (PCI), but the prognostic impact of CyC
alone or along with sCr on patients undergoing PCI has not been well
determined.
Methods: We measured CyC together with sCr in 266 consecutive patients under-
going percutaneous coronary intervention (PCI) from June 2013 to February 2014 in
our cardiovascular center. CyC and sCr were assessed at baseline and within 24 to
48 hours after contrast media exposure. Major adverse coronary events (including all-
cause mortality, myocardial infarction, and cardiac revascularization) were assessed
during a mean follow-up of 3.5 months.
Results: Within 24 to 48 hours after contrast media exposure, contrast-induced acute
kidney injury (deﬁned as a sCr increase 25%) occurred in 14 patients (5.26%). A CyCardiovascular Disease Clinical Research C141
